Abstract
During the past decade in the United States, Streptococcus pneumoniae has changed dramatically in the context of antimicrobial resistance. Resistance to multiple different antibiotic classes including beta-lactams (penicillins, cephalosporins, and beta-lactamase inhibitor combinations), macrolides, clindamycin, the tetracyclines, chloramphenicol, and trimethoprim-sulfamethoxazole (TMP/SMX) has emerged at high rates with this important respiratory tract pathogen. There is no question that the in vitro activity of these antimicrobial agents is substantially lower for many strains of S. pneumoniae than it was even a few years ago. The larger question is, however, what does this decrease in activity mean from a clinical perspective? Stated another way, does resistance defined according to current standards in the laboratory, translate into diminished effectiveness when these agents are used to treat patients with pneumococcal infections? It is this question that serves as the principal basis for this review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
